Literature DB >> 28730644

FungiScope -Global Emerging Fungal Infection Registry.

Danila Seidel1, Luisa A Durán Graeff1, Maria J G T Vehreschild1,2,3, Hilmar Wisplinghoff4,5,6, Maren Ziegler4, J Janne Vehreschild1,2,3, Blasius Liss7, Axel Hamprecht5, Philipp Köhler1,8, Zdenek Racil9, Nikolay Klimko10, Donald C Sheppard11, Raoul Herbrecht12, Anuradha Chowdhary13, Oliver A Cornely1,8,14.   

Abstract

Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late onset of treatment and inappropriate medication is associated with high mortality, thus, urging the need for a better understanding of these diseases. The purpose of FungiScope™ is to continuously collect clinical information and specimens to improve the knowledge on epidemiology and eventually improve patient management of these orphan diseases. FungiScope™ was founded in 2003, and today, collaborators from 66 countries support the registry. So far, clinical data of 794 cases have been entered using a web-based approach. Within the growing network of experts, new collaborations developed, leading to several publications of comprehensive analyses of patient subgroups identified from the registry. Data extracted from FungiScope™ have also been used as the sole control group for the approval of a new antifungal drug. Due to the rarity of these diseases, a global registry is an appropriate method of pooling the scarce and scattered information. Joining efforts across medical specialities and geographical borders is key for researching rare IFD. Here, we describe the structure and management of the FungiScope™ registry.
© 2017 Blackwell Verlag GmbH.

Entities:  

Keywords:  fungal infection; global cooperation; immunocompromised; orphan disease; registry

Mesh:

Year:  2017        PMID: 28730644     DOI: 10.1111/myc.12631

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  12 in total

1.  Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature.

Authors:  Rosanne Sprute; Jon Salmanton-García; Ertan Sal; Xhorxha Malaj; Zdeněk Ráčil; Carlos Ruiz de Alegría Puig; Iker Falces-Romero; Aleksandra Barać; Guillaume Desoubeaux; Anupma Jyoti Kindo; Arthur J Morris; René Pelletier; Joerg Steinmann; George R Thompson; Oliver A Cornely; Danila Seidel; Jannik Stemler
Journal:  J Antimicrob Chemother       Date:  2021-05-12       Impact factor: 5.790

2.  Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study.

Authors:  Philipp Koehler; Saskia von Stillfried; Jorge Garcia Borrega; Frieder Fuchs; Jon Salmanton-García; Fabian Pult; Boris Böll; Dennis A Eichenauer; Alexander Shimabukuro-Vornhagen; Oliver Kurzai; Peter Boor; Matthias Kochanek; Oliver A Cornely
Journal:  Eur Respir J       Date:  2022-05-05       Impact factor: 33.795

3.  Saprochaete clavata Invasive Infections - A New Threat to Hematological-Oncological Patients.

Authors:  Vladimir Buchta; Radka Bolehovská; Eva Hovorková; Oliver A Cornely; Danila Seidel; Pavel Žák
Journal:  Front Microbiol       Date:  2019-10-29       Impact factor: 5.640

4.  Characterization and outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports.

Authors:  Rosanne Sprute; Jon Salmanton-García; Ertan Sal; Xhorxha Malaj; Iker Falces-Romero; Lóránt Hatvani; Melina Heinemann; Nikolai Klimko; Leyre López-Soria; Joseph Meletiadis; Malik Shruti; Joerg Steinmann; Danila Seidel; Oliver A Cornely; Jannik Stemler
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

5.  Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.

Authors:  Danila Seidel; Michaela Simon; Rosanne Sprute; Matthias Lubnow; Katja Evert; Claudius Speer; Jessica Seeßle; Elham Khatamzas; Uta Merle; Christopher Behrens; Igor Wolfgang Blau; Philipp Enghard; Christian S Haas; Joerg Steinmann; Oliver Kurzai; Oliver A Cornely
Journal:  Mycoses       Date:  2021-11-16       Impact factor: 4.931

6.  Bloodstream Infections Caused by Magnusiomyces capitatus and Magnusiomyces clavatus: Epidemiological, Clinical, and Microbiological Features of Two Emerging Yeast Species.

Authors:  Janina Noster; Martin B Koeppel; Marie Desnos-Olivier; Maria Aigner; Oliver Bader; Karl Dichtl; Stephan Göttig; Andrea Haas; Oliver Kurzai; Arthur B Pranada; Yvonne Stelzer; Grit Walther; Axel Hamprecht
Journal:  Antimicrob Agents Chemother       Date:  2021-12-20       Impact factor: 5.191

7.  Valley Fever on the Rise-Searching for Microbial Antagonists to the Fungal Pathogen Coccidioides immitis.

Authors:  Antje Lauer; Joe Darryl Baal; Susan D Mendes; Kayla Nicole Casimiro; Alyce Kayes Passaglia; Alex Humberto Valenzuela; Gerry Guibert
Journal:  Microorganisms       Date:  2019-01-24

Review 8.  Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts.

Authors:  Spinello Antinori; Mario Corbellino; Carlo Parravicini
Journal:  Curr Fungal Infect Rep       Date:  2018-01-24

9.  Genomic and phenotypic analysis of COVID-19-associated pulmonary aspergillosis isolates of Aspergillus fumigatus.

Authors:  Jacob L Steenwyk; Matthew E Mead; Patrícia Alves de Castro; Clara Valero; André Damasio; Renato A C Dos Santos; Abigail L Labella; Yuanning Li; Sonja L Knowles; Huzefa A Raja; Nicholas H Oberlies; Xiaofan Zhou; Oliver A Cornely; Frieder Fuchs; Philipp Koehler; Gustavo H Goldman; Antonis Rokas
Journal:  bioRxiv       Date:  2020-11-06

Review 10.  Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review.

Authors:  Beatrijs Mertens; Ruth Van Daele; Melissa Depypere; Katrien Lagrou; Yves Debaveye; Joost Wauters; Stefaan Nijs; Willem-Jan Metsemakers; Isabel Spriet
Journal:  Antibiotics (Basel)       Date:  2022-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.